Corbus Pharmaceuticals Holdings, Inc.
Index- P/E- EPS (ttm)-10.15 Insider Own0.30% Shs Outstand4.16M Perf Week6.13%
Market Cap28.57M Forward P/E- EPS next Y-53.22 Insider Trans0.00% Shs Float4.15M Perf Month146.44%
Income-42.30M PEG- EPS next Q-4.09 Inst Own19.00% Short Float / Ratio3.52% / 0.33 Perf Quarter118.12%
Sales0.00M P/S- EPS this Y8.80% Inst Trans-91.93% Short Interest0.15M Perf Half Y38.63%
Book/sh7.94 P/B0.92 EPS next Y9.70% ROA-53.30% Target Price120.00 Perf Year-52.65%
Cash/sh15.06 P/C0.48 EPS next 5Y- ROE-91.30% 52W Range2.11 - 16.66 Perf YTD119.31%
Dividend- P/FCF- EPS past 5Y12.10% ROI- 52W High-56.36% Beta2.11
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low244.55% ATR0.95
Employees33 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)63.41 Volatility16.44% 22.04%
OptionableYes Debt/Eq0.58 EPS Q/Q-6.50% Profit Margin- Rel Volume0.78 Prev Close8.83
ShortableYes LT Debt/Eq0.48 EarningsMar 07 BMO Payout- Avg Volume445.46K Price7.27
Recom2.50 SMA2045.33% SMA5066.12% SMA20038.06% Volume348,907 Change-17.67%
Sep-08-20Downgrade ROTH Capital Buy → Neutral $40 → $3
Sep-08-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-08-20Downgrade Jefferies Buy → Hold $18 → $2.50
Sep-08-20Downgrade BTIG Research Buy → Neutral
Jul-07-20Initiated ROTH Capital Buy $40
Jun-17-20Initiated BTIG Research Buy $22
Mar-26-20Initiated Nomura Buy $12
Apr-05-19Initiated Jefferies Buy
Mar-20-19Initiated Oppenheimer Outperform $28
Jan-11-19Reiterated Cantor Fitzgerald Overweight $36 → $38
Show Previous Ratings
Mar-14-23 04:35PM
Mar-07-23 08:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-13-23 11:27AM
06:55AM Loading…
Nov-10-22 09:05AM
Nov-08-22 08:05AM
Nov-03-22 05:00PM
Oct-14-22 08:05AM
Sep-26-22 08:05AM
Sep-22-22 08:00AM
Sep-12-22 07:00AM
Aug-09-22 09:25AM
08:00AM Loading…
May-11-22 08:00AM
May-10-22 09:25AM
Apr-08-22 01:05PM
Mar-31-22 09:51AM
Mar-18-22 10:12AM
Mar-17-22 10:41AM
Mar-11-22 08:05AM
Mar-08-22 06:15PM
Mar-02-22 07:00AM
Jan-14-22 09:38AM
Jan-12-22 10:35AM
Dec-31-21 09:58AM
Dec-29-21 10:00AM
10:00AM Loading…
Dec-07-21 10:00AM
Nov-12-21 08:05AM
Nov-11-21 08:05AM
Nov-02-21 03:02PM
Oct-21-21 09:30AM
Sep-10-21 06:45AM
Aug-12-21 09:45AM
Jul-29-21 03:04PM
Jun-24-21 08:05AM
Jun-21-21 05:48PM
Jun-18-21 08:38AM
Jun-12-21 04:19AM
Jun-03-21 02:42AM
Jun-02-21 06:19AM
Jun-01-21 12:26PM
May-25-21 08:05AM
May-19-21 09:20AM
May-17-21 08:34AM
May-11-21 08:05AM
May-03-21 03:01PM
Apr-20-21 08:05AM
Mar-30-21 08:05AM
Mar-18-21 12:00PM
Mar-15-21 02:30PM
Mar-10-21 12:59AM
Mar-09-21 08:05AM
Mar-08-21 08:05AM
Mar-04-21 12:30PM
Feb-11-21 11:29AM
Feb-02-21 10:44AM
Jan-20-21 08:05AM
Jan-14-21 08:30AM
Jan-12-21 08:49AM
Jan-09-21 02:16AM
Dec-07-20 10:43PM
Dec-04-20 08:44AM
Dec-01-20 10:28AM
Nov-16-20 09:54AM
Nov-12-20 08:05AM
Nov-11-20 10:00AM
Nov-10-20 03:31PM
Nov-09-20 10:27AM
Nov-03-20 08:05AM
Oct-29-20 12:35PM
Oct-23-20 08:05AM
Oct-21-20 08:05AM
Oct-08-20 08:05AM
Oct-07-20 10:46AM
Oct-06-20 07:05AM
Oct-04-20 09:46AM
Sep-25-20 08:53AM
Sep-24-20 09:54AM
Sep-10-20 10:01AM
Sep-08-20 10:00AM
Sep-04-20 09:40AM
Aug-25-20 09:19AM
Aug-24-20 06:30AM
Aug-20-20 10:17AM
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moran Sean F.Chief Financial OfficerAug 10Buy0.2620,0005,198199,272Aug 10 10:16 AM
Millian Craig StuartChief Operating OfficerAug 10Buy0.255,0001,27227,000Aug 12 09:43 AM
Cohen YuvalChief Executive OfficerAug 10Buy0.263,8001,00398,230Aug 11 09:55 AM
Moran Sean F.Chief Financial OfficerMay 16Buy0.3012,0003,600179,272May 16 11:03 AM
Cohen YuvalChief Executive OfficerMay 16Buy0.2510,5002,62594,430May 16 10:41 AM